On Friday, McDermott International (NYSE:MDR)’s shares declined -2.11% to $4.65.
McDermott International, Inc. (MDR) declared its plan of following event:
On Thursday, September 17, he will be presenting at the Imperial Capital Global Opportunities Conference in New York, starting at 8:00 a.m. Central / 9:00 a.m. Eastern.
McDermott International, Inc. operates as an engineering, procurement, construction, and installation company worldwide. The company operates through three segments: Asia Pacific, Americas, and the Middle East. It focuses on designing and executing offshore oil and gas projects.
Microchip Technology Inc. (NASDAQ:MCHP)’s shares dropped -0.70% to $43.89.
Microchip Technology Inc. (MCHP), a leading provider of microcontroller, mixed-signal, analog and Flash-IP solutions, recently declared an expansion of the development platform for its growing portfolio of innovative 8-bit PIC® microcontrollers (MCUs) with Core-Independent Peripherals (CIPs). Designers can combine these building blocks to perform application functions autonomously, and they can be interconnected with an increasing amount of integrated Intelligent Analog peripherals. Because these functions are deterministically and reliably performed in hardware instead of software, CIPs enable system performance that is far beyond traditional MCUs.
In order to further reduce development time with these next-generation MCUs, Microchip is releasing Version 3.0 of the MPLAB® Code Configurator (MCC)-the most recent version of Microchip’s free graphical programming environment-and adding three new development boards. The Curiosity Development Board is an entry-level, cost-effective tool that comprises an integrated programmer and debugger together with options for easy external connectivity. The Explorer 8 Development Kit is a rapid proof-of-concept tool with extensive integration, and it supports the widest variety of 8-bit PIC MCUs. The PICDEM™ Lab II Development Board is a comprehensive development and experimentation tool, with an analog and mixed-signal focus. This development platform, when combined with the Core-Independent Peripherals, can significantly reduce total design time.
Microchip Technology Incorporated develops, manufactures, and sells semiconductor products for various embedded control applications. The company offers microcontrollers, such as 8-bit, 16-bit, and 32-bit microcontrollers under the PIC brand name; and 16-bit dsPIC digital signal controllers, in addition to provides microcontrollers for automotive networking, computing, lighting, power supplies, wireless communication, and wireless audio applications.
At the end of Friday’s trade, U.S. Silica Holdings Inc (NYSE:SLCA)‘s shares dipped -6.75% to $17.74.
U.S. Silica Holdings, Inc. (SLCA) declared that members of the administration team will take part in the 6th Annual Credit Suisse Small/Mid Cap Conference
Sept. 16, 2015
Waldorf Astoria Hotel – New York, NY
U.S. Silica Holdings, Inc. produces and sells commercial silica in the United States. It operates through two segments, Oil & Gas Proppants, and Industrial & Specialty Products. The company offers whole grain commercial silica products to be used as fracturing sand in connection with oil and natural gas recovery, in addition to sells its whole grain silica products in various size distributions, grain shapes, and chemical purity levels for manufacturing glass products.
AstraZeneca plc (ADR) (NYSE:AZN), ended its Friday’s trading session with 0.06% gain, and closed at $33.30.
AstraZeneca recently added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will enhance manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.
AstraZeneca plans to start staffing the facility right away to support refurbishment and infrastructure improvements. Once complete, the site is predictable to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations.
In the longer- term, this site could create up to 400 highly skilled jobs, subject to relevant approvals by the local authorities. The facility wills eventually double the biologics manufacturing capacity in the US to meet the needs of the maturing AstraZeneca pipeline. Presently biologics make up 50 percent of the company’s pipeline with more than 120 ongoing programs, counting over 30 in clinical development.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products comprise Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
